Gilead Sciences (GILD) Cash from Operations Growth (3y) (2012 - 2026)
Gilead Sciences (GILD) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
73.44% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
45.52% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-8.27% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-2.98% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
43.03% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
27.18% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
13.41% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
29.22% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-28.10% |
| 10 |
Novartis Ag |
109.78 Bn |
109.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
13.41% |
| Dec 31, 2025 |
9.03% |
| Sep 30, 2025 |
12.79% |
| Jun 30, 2025 |
-22.87% |
| Mar 31, 2025 |
-1.53% |
| Dec 31, 2024 |
-2.45% |
| Sep 30, 2024 |
9.82% |
| Jun 30, 2024 |
-16.98% |
| Mar 31, 2024 |
-5.27% |
| Dec 31, 2023 |
4.22% |
| Sep 30, 2023 |
-7.95% |
| Jun 30, 2023 |
-3.05% |
| Mar 31, 2023 |
6.69% |
| Dec 31, 2022 |
-0.17% |
| Sep 30, 2022 |
2.68% |
| Jun 30, 2022 |
-8.37% |
| Mar 31, 2022 |
5.28% |
| Dec 31, 2021 |
10.98% |
| Sep 30, 2021 |
13.72% |
| Jun 30, 2021 |
13.76% |
